Targeting the root cause of acute myeloid leukemia
Therapeutic Targeting of Human AML Stem Cells
This study is looking for better ways to treat acute myeloid leukemia (AML) by focusing on the special cells that help the cancer grow, and it aims to find out how to target these cells more effectively, especially for newly diagnosed patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10903988 on NIH RePORTER |
What this research studies
This research focuses on developing better treatments for acute myeloid leukemia (AML) by targeting leukemia stem cells (LSCs), which are believed to drive the disease. The researchers aim to identify common characteristics of these LSCs to create effective therapies that can overcome the challenges posed by their diversity within patients. A key aspect of the approach involves inhibiting a specific protein, BCL2, which has shown promise in selectively eradicating LSCs and improving outcomes for newly diagnosed AML patients. The study also seeks to understand the mechanisms behind treatment relapse to enhance long-term effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are newly starting treatment.
Not a fit: Patients with other types of leukemia or those who have already undergone multiple treatments for AML may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for AML, potentially improving survival rates and reducing relapse.
How similar studies have performed: Previous research has shown promising results in targeting leukemia stem cells, particularly with BCL2 inhibitors, indicating a potential breakthrough in AML treatment.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Jordan, Craig T. — University of Colorado Denver
- Study coordinator: Jordan, Craig T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.